Ontology highlight
ABSTRACT: Background
Neurocognitive deficits are a recognized late effect of curative brain tumor therapy. We evaluated the feasibility, tolerance, and impact of a pilot pharmacologic intervention with the acetylcholinesterase (AChe) inhibitor, donepezil, in pediatric brain tumor (BT) survivors at risk for neurocognitive dysfunction.Procedure
A single institution open-label pilot study was conducted in childhood BT survivors: ≥1 year from cancer treatment; and who received >23.5 Gy cranial radiation therapy (RT). Toxicity, adherence and neurocognitive outcomes were evaluated at baseline and serially during 24 weeks of donepezil, and following a 12-week washout period off drug.Results
From a pool of subjects, 13 were successfully contacted and screened, and 11 met all eligibil
SUBMITTER: Castellino SM
PROVIDER: S-EPMC3345166 | biostudies-literature | 2012 Sep
REPOSITORIES: biostudies-literature